ÍøºìºÚÁÏ

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2* early breast cancer with intermediate-high or high risk for disease recurrence who completed…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - 130 Years

Sexes

All

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications…

Investigator

Karen Daily

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All